Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$184.36
-2.0%
$195.22
$153.58
$218.66
$326.13B0.566.08 million shs2.93 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$47.23
-0.8%
$55.06
$39.35
$63.33
$96.12B0.3913.01 million shs7.20 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$156.45
-0.5%
$158.35
$140.68
$169.99
$376.43B0.427.87 million shs2.07 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$77.70
-1.8%
$85.91
$75.93
$134.63
$195.11B0.4312.07 million shs4.06 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$22.82
+0.1%
$24.15
$20.92
$31.54
$129.42B0.5840.34 million shs17.79 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.29%-3.73%+0.95%-2.63%+15.58%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.06%-5.13%-13.67%-17.05%+8.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.70%+0.58%+4.50%+2.46%+5.72%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.02%-7.20%-2.49%-10.10%-39.34%
Pfizer Inc. stock logo
PFE
Pfizer
-0.61%-6.69%+0.61%-11.80%-17.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.8248 of 5 stars
3.44.03.33.93.42.51.3
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.7022 of 5 stars
3.23.04.24.04.03.30.0
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.7931 of 5 stars
3.33.04.23.93.42.51.3
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.33.05.03.94.02.53.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9992 of 5 stars
4.33.04.24.34.03.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.89
Moderate Buy$211.4114.67% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.32
Hold$58.0022.80% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.63
Moderate Buy$171.829.83% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$111.1343.02% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1727.81% Upside

Current Analyst Ratings Breakdown

Latest ABBV, JNJ, BMY, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/29/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$214.00 ➝ $216.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.00
4/28/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.00
4/25/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/24/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/23/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $68.00
4/22/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$210.00
4/22/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
4/22/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$57.37B5.68$13.63 per share13.53$1.90 per share97.03
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$47.64B2.02$4.98 per share9.48$8.08 per share5.85
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.21$12.86 per share12.17$29.69 per share5.27
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$63.92B3.05$2.70 per share28.82$14.85 per share5.23
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.07$3.58 per share6.38$15.81 per share1.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3576.8213.191.627.59%296.28%12.65%7/24/2025 (Estimated)
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$8.95B$2.67N/A7.762.07-18.53%13.93%2.46%7/25/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9923.5314.132.5618.20%34.24%13.63%7/16/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8711.557.850.7726.67%45.35%17.36%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3816.187.530.6412.62%19.47%8.09%N/A

Latest ABBV, JNJ, BMY, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
4/24/2025Q1 2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.56%+6.04%279.15%53 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.485.25%+6.38%92.88%17 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.32%+5.43%57.84%64 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.17%+5.73%47.16%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.54%+2.50%124.64%16 Years

Latest ABBV, JNJ, BMY, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
3/3/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.624.14%4/4/20254/4/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.90
1.25
1.15
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,3002.04 billion2.03 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.51 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

3 Ultra-High Yield Dividend Stocks to Buy This May
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Down 1.8% - Here's Why
Pfizer Has Unreasonable Whiff Of The Marlboro Man

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$184.36 -3.73 (-1.98%)
As of 11:17 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol-Myers Squibb stock logo

Bristol-Myers Squibb NYSE:BMY

$47.23 -0.39 (-0.82%)
As of 11:17 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$156.45 -0.85 (-0.54%)
As of 11:17 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$77.70 -1.42 (-1.79%)
As of 11:17 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$22.82 +0.03 (+0.13%)
As of 11:17 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.